Since then, out of the original portfolio of seven candidates, six have been approved for use in the UK to date.44 But with six vaccines to choose from, it is noteworthy that only three—AstraZeneca, Pfizer and Moderna—have actually been deployed in the UK and also that the only new contracts signed in 2021 were with Pfizer and Moderna.45 The UK’s vaccine supply for 2022 and 2023 now relies primarily on just these two companies, both manufacturers of mRNA vaccines.46

Since then, out of the original portfolio of seven candidates, six have been approved for use in the UK to date.44 But with six vaccines to choose from, it is noteworthy that only three—AstraZeneca, Pfizer and Moderna—have actually been deployed in the UK and also that the only new contracts signed in 2021 were with Pfizer and Moderna.45 The UK’s vaccine supply for 2022 and 2023 now relies primarily on just these two companies, both manufacturers of mRNA vaccines.46 Type: conclusion | Number: 19 | Response status: not_addressed Government response: 5: PAC conclusion: After starting with a portfolio of seven candidates, the UK’s vaccine supply for 2022 and 2023 now relies primarily on just two, yet many of the risks that the ‘portfolio’ approach was intended to mitigate remain. 5: PAC recommendation: The Department and the Vaccine Taskforce sho